These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 16997628)

  • 21. [Clinical pharmacology and therapeutic results of a specific antagonist in disorders of gastroduodenal and peripheral motility].
    Bertrand J; Thillier JL
    Sem Hop; 1980 Oct 18-25; 56(39-40):1579-81. PubMed ID: 6255572
    [No Abstract]   [Full Text] [Related]  

  • 22. [Effect of prokinetic drugs inhibiting dopaminergic system on gallbladder motility in subjects with duodenal ulcer].
    Szabelska K; Chojnacki J; Grzegorczyk K; Mamos A
    Pol Merkur Lekarski; 1999 Apr; 6(34):188-91. PubMed ID: 10391057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Domperidone affects the interdigestive motility in the jejunum (author's transl)].
    Richter A; Erckenbrecht J; Wienbeck M
    Z Gastroenterol; 1981 Dec; 19(12):767-71. PubMed ID: 7034388
    [No Abstract]   [Full Text] [Related]  

  • 24. Use of peripheral dopamine receptor antagonist in gynaecology in certain borderline cases.
    Kis Csitári I
    Ther Hung; 1987; 35(1):35-9. PubMed ID: 3438864
    [No Abstract]   [Full Text] [Related]  

  • 25. Cardiac safety concerns for domperidone, an antiemetic and prokinetic, and galactogogue medicine.
    Doggrell SA; Hancox JC
    Expert Opin Drug Saf; 2014 Jan; 13(1):131-8. PubMed ID: 24147629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is dopamine an inhibitory modulator of gastrointestinal motility?
    Schuurkes JA; Van Nueten JM
    Scand J Gastroenterol Suppl; 1981; 67():33-6. PubMed ID: 6941419
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Domperidone and sudden death.
    Prescrire Int; 2006 Dec; 15(86):226. PubMed ID: 17167933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: The diagnosis and management of gastroparesis.
    Haans JJ; Masclee AA
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():37-46. PubMed ID: 18081647
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current role of antidopaminergic drugs in pediatrics].
    Cinquetti M; Bonetti P; Bertamini P
    Pediatr Med Chir; 2000; 22(1):1-7. PubMed ID: 11387760
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of oral erythromycin for the treatment of gastrointestinal dysmotility in preterm infants.
    Ng PC
    Neonatology; 2009; 95(2):97-104. PubMed ID: 19218823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Motility-effective drugs for therapy of gastrointestinal functional disorders].
    Weihrauch TR; Kilbinger H
    Dtsch Med Wochenschr; 1982 Sep; 107(35):1323-8. PubMed ID: 6749465
    [No Abstract]   [Full Text] [Related]  

  • 32. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia.
    Fowler JA; Bettinger TL; Argo TR
    Clin Ther; 2008 Feb; 30(2):231-48. PubMed ID: 18343262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of severe snoring with a combination of pseudoephedrine sulfate and domperidone.
    Larrain A; Hudson M; Dominitz JA; Pope CE
    J Clin Sleep Med; 2006 Jan; 2(1):21-5. PubMed ID: 17557432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Some possible gynaecological indications for peripheral antidopamine therapy.
    Varga A; Lovas J
    Ther Hung; 1992; 40(1):28-30. PubMed ID: 1585281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of dopamine D2 receptor antagonists on gastrointestinal motility].
    Mizumoto A; Ito A
    Nihon Heikatsukin Gakkai Zasshi; 1990 Apr; 26(2):65-9. PubMed ID: 2273688
    [No Abstract]   [Full Text] [Related]  

  • 36. Short-term effect of domperidone on gastroesophageal reflux in newborns assessed by combined intraluminal impedance and pH monitoring.
    Cresi F; Marinaccio C; Russo MC; Miniero R; Silvestro L
    J Perinatol; 2008 Nov; 28(11):766-70. PubMed ID: 18580879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Insight: from disturbed motility to disordered movement--a review of the clinical benefits and medicolegal risks of metoclopramide.
    Pasricha PJ; Pehlivanov N; Sugumar A; Jankovic J
    Nat Clin Pract Gastroenterol Hepatol; 2006 Mar; 3(3):138-48. PubMed ID: 16511548
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Access options for withdrawn motility-modifying agents.
    Jones MP
    Am J Gastroenterol; 2002 Sep; 97(9):2184-8. PubMed ID: 12358230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Diseases of gastrointestinal motility. Treatment with motility-modifying substances].
    Storr M; Allescher HD
    Med Monatsschr Pharm; 2003 Aug; 26(8):260-9. PubMed ID: 12953379
    [No Abstract]   [Full Text] [Related]  

  • 40. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia.
    Hiyama T; Yoshihara M; Matsuo K; Kusunoki H; Kamada T; Ito M; Tanaka S; Nishi N; Chayama K; Haruma K
    J Gastroenterol Hepatol; 2007 Mar; 22(3):304-10. PubMed ID: 17295758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.